Methods of Treating Wounds Using Cathepsin K Inhibitors
AssigneeUniversity of Wyoming
InventorSreejayan Nair
Life of this patent
Estimating the term…
Abstract
Diabetic wounds have elevated levels of cathepsin K, a protease enzyme, which degrades proteins, such as collagen, causing delayed wound healing. By targeting cathepsin K, diabetic wound healing is ameliorated. Methods and devices for treatment include intradermal injection of odanacatib at or adjacent a wound. Methods and devices for treatment include topical application of pharmacological inhibitors of cathepsin K, for example, in the form of gel, powder, or bandage. Other methods and systems include localized genetic knock out of the cathepsin K gene by topical application of a small interfering RNA (siRNA) or antisense oligonucleotide to aid in wound healing.
Claims20
A method for treating a skin wound in a pre-diabetic, hypoglycemic, or diabetic subject or a subject having a chronic wound, comprising:
- administering to the skin wound a therapeutic composition comprising an agent that degrades or inhibits cathepsin K;
- wherein the agent comprises at least one of odanacatib, cathepsin K inhibitor II, or an siRNA that has a sequence that is complementary to a nucleic acid sequence encoding cathepsin K;
- and,
- wherein the therapeutic composition is administered topically, intradermally, or subcutaneously to the skin wound.
A dermal wound dressing comprising:
- a porous support structure;
- and
- a therapeutic composition comprising an agent comprising at least one of odanacatib, cathepsin K inhibitor II, or an siRNA that has a sequence that is complementary to a nucleic acid sequence encoding cathepsin K.
Dependencies are inferred from the claim text.